Passage Bio, Inc.
- PASG
- NASDAQ
- Biotechnology
- Gene Therapy (AAV)
- CNS/Brain Disorders
- Rare Disease Treatments
$3.50
Today −2.78%Quote Oct 16, 2026, 08:00 PM UTC
−30.56%over the last month
Max drawdown −30.6%From 1-month high −30.6%3 months −27.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$11.3M
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$10.00
+185.7% from here
Floor
$3.44
1.8% below price
Where the price sits
11 analysts
Analyst range, low to high
$7.00$15.00
- Price $3.50
- Resistance $3.86
- Consensus $10.00
The price is just above its floor. Analysts' average target sits about 186% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PASGPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
24